Regulatory Scrutiny Intensifies for Hims & Hers Following Super Bowl Ad

The telehealth provider Hims & Hers finds itself navigating turbulent regulatory waters. Its recent expansion into the multi-billion dollar testosterone therapy market has been immediately overshadowed by a significant confrontation with the U.S. Food and Drug Administration (FDA). The clash was triggered by a multi-million dollar Super Bowl advertisement for weight-loss medications that the agency has flagged for an “egregious” violation of marketing rules, raising questions about potential constraints on the company’s aggressive growth strategy.

FDA Launches Unusually Sharp Rebuke

In an unusually forceful public statement, FDA Commissioner Marty Makary took a definitive stance. He characterized the advertisement for the company’s GLP-1 copycat drugs as the “most obvious” rule violation he was aware of, citing a presentation that communicated only the benefits of the treatment while omitting all mention of associated risks or potential side effects. This criticism was part of a broader enforcement initiative; the agency issued approximately 100 warning letters to pharmaceutical advertisers this past Friday.

This regulatory push is backed by a recent Executive Order from President Trump, which calls for stricter controls on the direct-to-consumer marketing of medications. Adding a layer of complexity, the FDA is asserting jurisdiction in this area, which has traditionally fallen under the purview of the Federal Trade Commission (FTC). Even prior to the ad’s airing, industry critics had labeled the commercial “incredibly irresponsible” and demanded its withdrawal.

Expansion Continues Amidst Mounting Pressure

Seemingly undeterred, Hims & Hers concurrently announced a major push into the testosterone market. Through an exclusive partnership with Marius Pharmaceuticals, the company plans to bring the orally administered drug KYZATREX® to market by 2026. This will be supplemented by immediately available compounded alternatives. CEO Andrew Dudum identified “stigma, outdated treatments, and high costs” as key market barriers that the company aims to dismantle.

Should investors sell immediately? Or is it worth buying Hims & Hers?

The strategic move appears sound from a commercial perspective. The testosterone market is valued at an estimated $2 billion, with a potential target audience of roughly 20 million American men. Furthermore, this diversification provides Hims & Hers a crucial degree of independence from the GLP-1 drug category, a necessity after Novo Nordisk terminated its compounding partnership with the company.

Balancing Robust Growth with New Regulatory Hurdles

Recent quarterly results highlight this period of transition. The company’s subscriber base grew impressively by 31 percent to reach 2.4 million. However, performance in the GLP-1 segment declined, contributing to a narrow revenue miss; the reported $544.8 million fell just short of the $549.87 million forecast. Despite this, management has reaffirmed its full-year revenue guidance of $2.3 to $2.4 billion.

A critical question now looms: how sustainable is the business model if the FDA continues to tighten advertising regulations? The agency’s explicit clarification that compounded products “carry a higher risk for patients than FDA-approved drugs” has the potential to fundamentally challenge the company’s core marketing strategy. The Q3 results, due in November, are anticipated to provide initial answers, revealing whether the momentum from the testosterone expansion can successfully counter the growing regulatory headwinds.